95499-72-2

Basic information

• Product Name: Benzeneacetic acid, -alpha-,-alpha--dimethyl-4-(2-methylpropyl)- (9CI)
• Synonyms: Benzeneacetic acid, -alpha-,-alpha--dimethyl-4-(2-methylpropyl)- (9CI)
• CAS NO: 95499-72-2
• Molecular Formula: C₁₄H₂₀O₂
• Molecular Weight: 220.3074
• Product Categories: PHENYL
• Mol File: 95499-72-2.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 328.3°Cat760mmHg
• Flash Point: 225.4°C
• Appearance: /
• Density: 1.015g/cm³
• Vapor Pressure: 7.7E-05mmHg at 25°C
• Refractive Index: 1.51
• CAS DataBase Reference: Benzeneacetic acid, -alpha-,-alpha--dimethyl-4-(2-methylpropyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzeneacetic acid, -alpha-,-alpha--dimethyl-4-(2-methylpropyl)- (9CI)(95499-72-2)
• EPA Substance Registry System: Benzeneacetic acid, -alpha-,-alpha--dimethyl-4-(2-methylpropyl)- (9CI)(95499-72-2)

Safety Data

• Hazardous Substances Data: 95499-72-2(Hazardous Substances Data)

Usage

InChI:InChI=1/C14H20O2/c1-10(2)9-11-5-7-12(8-6-11)14(3,4)13(15)16/h5-8,10H,9H2,1-4H3,(H,15,16)

Upstream product

• 69326-79-0 C₁₄H₁₉N 
• 61566-34-5 (+/-)-ibuprofen methyl ester 
• 15687-27-1 ibuprofen 
• 74-88-4 methyl iodide 

Downstream Products

• 1382488-06-3 1-(2-chlorobenzyl)-2-[1-(4-isobutylphenyl)-1-methylethyl]-1H-benzimidazole 
• 1382488-04-1 2-(2-(4-isobutylphenyl)propan-2-yl)-1H-benzimidazole 
• 1382488-02-9 N-(2-aminophenyl)-2-(4-isobutylphenyl)-2-methylpropanamide 
• 110319-75-0 N-hydroxy-N-methyl-2-methyl-2-<4-(2-methylpropyl)phenyl>propionamide 

Relevant articles and documents

Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen

Inhibition of fatty acid amide hydrolase (FAAH) reduces the gastrointestinal damage produced by non-steroidal anti-inflammatory agents such as sulindac and indomethacin in experimental animals, suggesting that a dual-action FAAH-cyclooxygenase (COX) inhib

Synthesis and Pharmacological Evaluation of New Chemical Entities from Ibuprofen as Novel Analgesic Candidates

Non-steroidal anti-inflammatory drugs (NSAIDs) are the first choice of drugs that are normally used for the treatment of pain and inflammation. Ibuprofen (I) and its analogues as the most widely used NSAIDs have been synthesized in recent years. In an effort to establish new candidates with improved analgesic properties, derivatives (II-VII) with substituted aromatic as well as aliphatic moieties were synthesized in this experiment and evaluated in formalin test with rats. The results were compared to ibuprofen and control groups. Findings indicated that derivatives with new alkylphenyl rings (VI and VII) had some similar or more analgesic activities relative to the control and ibuprofen groups, respectively; which could be justified as to more alkyl and phenyl groups instead of p-isobutylphenyl moiety in I.

Identification of novel benzimidazole derivatives as inhibitors of leukotriene biosynthesis by virtual screening targeting 5-lipoxygenase- activating protein (FLAP)

Pharmacological suppression of leukotriene biosynthesis by 5-lipoxygenase (5-LO)-activating protein (FLAP) inhibitors is a promising strategy to intervene with inflammatory, allergic and cardiovascular diseases. Virtual screening targeting FLAP based on a combined ligand- and structure-based pharmacophore model led to the identification of 1-(2-chlorobenzyl)-2-(1-(4-isobutylphenyl) ethyl)-1H-benzimidazole (7) as developable candidate. Compound 7 potently suppressed leukotriene formation in intact neutrophils (IC50 = 0.31 μM) but essentially failed to directly inhibit 5-LO suggesting that interaction with FLAP causes inhibition of leukotriene synthesis. For structural optimization, a series of 46 benzimidazole-based derivatives of 7 were synthesized leading to more potent analogues (70-72, 82) with IC50 = 0.12-0.19 μM in intact neutrophils. Together, our results disclose the benzimidazole scaffold bearing an ibuprofen fingerprint as a new chemotype for further development of anti-leukotriene agents.